Paper Details

  1. Home
  2. Paper Details

Can Phosphodiesterase 4 Inhibitor Therapy Be Used in Respiratory Diseases Other Than Chronic Obstructive Pulmonary Disease?

Author: ChalasaniRoopa, GeorgeKitty, GeorgeSheeba, GoonathilakeMastiyage R, InyangBithaiah, Jean-BaptisteWilford, KoshyFeeba Sam, MohammedLubna, PoudelPrakar, WaqarSara, Yusuf AliAmina

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Overview

Phosphodiesterase 4 (PDE4) inhibitors have potential for treating various respiratory diseases. This review summarizes the therapeutic action, limitations, recent successes, and future targets of PDE4 inhibitors in respiratory diseases other than COPD, highlighting the need for balancing efficacy with minimizing side effects.
Paper Details　
Original Abstract of the Article :
Selective phosphodiesterase 4 (PDE4) inhibitors have been extensively studied for the treatment of various respiratory diseases due to their broad anti-inflammatory and/or bronchodilator effects. Roflumilast, an oral selective PDE4 inhibitor, is currently used as a second-line treatment in patients ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9392891/

データ提供：米国国立医学図書館（NLM）

Beyond COPD: Exploring PDE4 Inhibitors in Other Respiratory Diseases

This review explores the potential of PDE4 inhibitors, a class of medications known to have anti-inflammatory and bronchodilator effects, to treat a range of respiratory diseases beyond chronic obstructive pulmonary disease (COPD). Imagine it as a desert traveler discovering new routes through a vast and unexplored landscape – the researchers are seeking new applications for PDE4 inhibitors in treating respiratory ailments.

The Promise of PDE4 Inhibitors

The review discusses the potential benefits of PDE4 inhibitors in treating asthma, chronic cough, allergic rhinitis, and cystic fibrosis. It's like discovering a new oasis that offers relief from the harsh desert environment. This review highlights the versatility of these medications and their potential to address a wider range of respiratory conditions.

New Horizons in Respiratory Therapy

This review emphasizes the need for further research to fully understand the efficacy and safety of PDE4 inhibitors in treating respiratory diseases other than COPD. It's like charting a new course across a vast and unknown desert – careful exploration is essential to uncover the full potential of these medications. This review encourages ongoing research to expand the therapeutic applications of PDE4 inhibitors.

Dr. Camel's Conclusion

This review highlights the exciting potential of PDE4 inhibitors to address a wide range of respiratory diseases beyond COPD. It's a reminder that the search for new and effective treatments is an ongoing journey, and that exploring new horizons in therapeutic research is essential to finding solutions for the challenges facing patients with respiratory conditions.

Date :
  1. Date Completed n.d.
  2. Date Revised 2022-08-27
Further Info :

Pubmed ID

36017299

DOI: Digital Object Identifier

PMC9392891

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.